Ladenburg ‘growing more confident’ in path for Palisade Bio’s LB1148

After having recently spoken with Palisade Bio management regarding further steps in the development of LB1148, Ladenburg analyst Aydin Huseynov is "growing more confident in the regulatory path LB1148 may take" given that the team said LB1148 may proceed in the currently paused Phase 3 randomized study, albeit with a new co-primary endpoint, once the Phase 2 adhesions data are available. The firm, which calls this potential plan one that "appears to be the most rational scenario," thinks such a modified Phase 3 randomized study "would position LB1148 as an adhesion prevention drug, with first-in-class status on the market." Ladenburg maintains a Buy rating and $25 price target on Palisade Bio shares.